Premium
Induction Hedgehog pathway inhibition followed by combined‐modality radiotherapy for basal cell carcinoma
Author(s) -
Raleigh D.R.,
Algazi A.,
Arron S.T.,
Neuhaus I.M.,
Yom S.S.
Publication year - 2015
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.13748
Subject(s) - vismodegib , basal cell carcinoma , hedgehog signaling pathway , medicine , radiation therapy , hedgehog , lesion , basal cell , oncology , cancer research , surgery , biology , signal transduction , biochemistry , gene
Summary Basal cell carcinoma ( BCC ), the most common cancer in the U.S.A., is treated primarily with local excision. In some cases, lesion size, location or extent prevent complete resection. Locally advanced BCC responds to systemic therapy with the Hedgehog pathway inhibitor vismodegib, but withdrawal of treatment may result in disease relapse. Here we present a case of locally advanced auricular BCC treated with induction vismodegib and radiation, resulting in durable local control and an acceptable level of acute toxicity.